Market research projects 7.5% annual growth in limb prosthetics. What that projection does and doesn't measure.

This coverage has been consolidated. Both feed items this session were already fully reported. See: A market research firm is forecasting 7.5% annual growth for limb prosthetics (Eli Park, August 14) and Fortune Business Insights published a market forecast for ‘robotic prosthetics’ through 2034 (Eli Park, August 14). This file should be deleted before the next deploy.

Two market research reports landed this week in the prosthetics industry feed. One, distributed via EIN News, puts the near-term compound annual growth rate for the limb prosthetics market at 7.5 percent. The other, from Fortune Business Insights, projects the robotic prosthetics segment through 2034. Both are in the familiar genre of market intelligence reports — vendor-commissioned or independently sold growth forecasts aimed at investors, device manufacturers, and health systems making capital and product decisions.

These reports are not patient-facing, and they are not describing patient access. Here is what they are describing, and what the gap is between the projection and the appointment room.

What market forecasts actually count

A market-size projection for prosthetics is a dollar-volume figure. It counts the total estimated value of transactions in a given period: devices sold, components ordered, procedures billed to payers, out-of-pocket purchases, and government procurement. When that figure is projected to grow at 7.5 percent annually, it means forecasters expect the aggregate dollar amount of those transactions to increase at that rate — not that the number of people receiving devices is growing at that rate, not that device quality is advancing at that rate, and not that access to advanced prosthetics is expanding at that rate.

The drivers of that growth can include any of the following, in varying combinations: an increasing number of people living with limb loss (the U.S. has an estimated two million people with limb loss, a figure that has been climbing as diabetes-related vascular disease drives a rising rate of lower-limb amputations); higher per-device prices as advanced-technology components command premium pricing; expansion of prosthetics markets in middle-income countries as global healthcare infrastructure develops; and replacement-cycle volume as the existing patient population renews devices on schedule.

Market growth can be driven almost entirely by higher-price devices at the premium end, serving a small fraction of users — while the access picture for the majority remains static or worsens within the same forecast period. Market size and market access are not the same variable.

The coding bottleneck

For a prosthetic device or component to be reimbursed by Medicare or most commercial insurers, it needs a billing code. In the United States, prosthetics and orthotics use Healthcare Common Procedure Coding System (HCPCS) L-codes — a four-character alphanumeric system that identifies a device, defines its functional category, and determines the applicable reimbursement rate.

New technology does not automatically receive an L-code. A device can be FDA-cleared, commercially available, and clinically in use — and still have no L-code, which means no billable pathway through Medicare or commercial insurance. Manufacturers submit coding requests; the American Orthotic and Prosthetic Association and other industry groups advocate for new codes; CMS evaluates and assigns. The timeline from commercial availability to assigned code to active reimbursement can run several years. During that interval, the device exists in the market — it can be counted in a market-size forecast — but it cannot reach most patients through third-party payment unless an insurer makes an exceptional coverage decision outside the standard code system.

Several of the advanced robotic and powered prosthetics that drive attention in the “growth market” narrative sit in or near this zone: devices that have cleared FDA, are commercially sold, and are referenced in market research projections, but carry limited or no standard L-code coverage for the functional category they occupy.

The functional classification question

For patients who use Medicare, access to prosthetic devices is also gated by a functional classification system. Medicare assigns people with limb loss a K-level — K0 through K4 — that is supposed to reflect their ambulatory potential with an appropriate prosthesis, not what they currently have.

K0 is no ambulatory potential; Medicare does not cover a prosthetic device. K1 is limited indoor ambulation on level surfaces. K2 is limited community ambulation. K3 is unlimited community ambulation with the ability to traverse barriers. K4 is high activity — athletic, occupational, or rehabilitative demands that exceed typical community ambulation.

Many of the advanced components appearing in robotic prosthetics market reports — microprocessor-controlled knees, powered ankles, multifunction upper-limb systems — are categorized in Medicare policy as appropriate for K3 and K4 users. A patient assessed as K2 cannot access those components through Medicare, regardless of what the market is producing and regardless of what a prosthetist might clinically recommend. The K-level is assigned by the treating physician and certified prosthetist, but it is also a point at which insurers push back — challenging K3 classifications and requiring additional documentation or peer review before approving devices at that tier.

Local coverage determinations

Below the national coverage framework, individual Medicare Administrative Contractors (MACs) issue Local Coverage Determinations (LCDs) that define, region by region, the specific documentation requirements and clinical criteria that apply to a prosthetic claim. Two patients in different MAC jurisdictions, with the same diagnosis, the same functional presentation, and the same prescribed device, can face different coverage rules because the LCDs governing their claims differ.

This is not a theoretical edge case. The prosthetics LCDs issued by MACs have been the subject of sustained industry advocacy and legal challenge, because they can be stricter than clinical evidence supports, and because the criteria embedded in an LCD can effectively exclude devices that are appropriate in the professional literature. When the industry tracks a new LCD revision through comment and finalization, it is often because the draft language, if finalized, would narrow coverage in a way that removes access to devices currently reimbursed.

A market-size forecast does not know any of this. The forecast counts the device as sold.

What market growth actually signals

Market growth in prosthetics is not meaningless. It reflects real investment in technology development, and that investment does eventually reach patients — through devices that are better than what came before, through clinical evidence that builds the case for expanded coverage criteria, through manufacturing scale that lowers costs enough that some devices become accessible without insurance. The timeline on any of those channels is measured in years to decades, not forecast periods.

The more direct signal, for a patient trying to understand what they can access today or in the next year, is not the market-size projection. It is whether CMS has updated a National Coverage Determination for the device category they need, whether the relevant MAC’s LCD has been revised, and whether their functional classification was assessed and documented accurately at their most recent clinical evaluation.

A prosthetist who is current on CMS policy and LCD revisions in their MAC jurisdiction is a more useful resource for that question than any market research report.

What to watch

The O&P field has been pushing for LCD reform on several fronts — particularly around documentation criteria that trigger automatic technical denials, functional classification criteria that gate K-level assignments, and the coding lag for newer device categories. If any of those advocacy efforts produce CMS action in late 2026 or into 2027, the connection between market growth and patient access would begin to close in a visible way. Until then, the two numbers — the market projection and the coverage landscape — are measuring different things with different audiences in mind.

The Amputee Coalition and the American Orthotic and Prosthetic Association both track policy developments on coverage criteria and LCD revisions. Those are the sources to watch if you are following this for patient-access reasons rather than investment reasons.

---

Amputee News covers prosthetics policy and market developments as reported. This article does not provide individualized medical, insurance, or device-fitting advice. Medicare coverage for prosthetic devices depends on your functional classification, your payer, and the current LCD in your MAC jurisdiction. For questions about your specific coverage, contact your prosthetist, your plan, or a State Health Insurance Assistance Program (SHIP) counselor.